Breast Cancer Liquid Biopsy Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)
Breast Cancer Liquid Biopsy Market Analysis:
The market size of the Breast Cancer Liquid Biopsy is projected to experience significant growth from USD 334.44 million in 2023 to USD 875.73 million by 2028, with a compound annual growth rate (CAGR) of 21.23% during the forecast period of 2023–2028. However, the COVID-19 pandemic has had a detrimental impact on the market’s growth. Lockdown measures implemented in various countries to curb the spread of the virus have resulted in hospitals, clinics, and diagnostic centers being unable to provide biopsy services. A study conducted in the United Kingdom and published in The Lancet Oncology in March 2021 revealed that delayed cancer diagnoses due to the pandemic will significantly reduce 1- and 5-year survival rates for breast, colorectal, esophageal, and lung cancer patients. As lockdowns persist and screening services continue to be affected, the survivability of cancer patients is expected to decrease.
On a positive note, an increase in regulatory approvals is anticipated to have a favorable impact on the market. For instance, in June 2019, the United States Food and Drug Administration (FDA) granted regulatory approval to QIAGEN’s therascreen PIK3CA RGQ PCR Kit. This approval allows the device to be used as a companion diagnostic assay for the detection of PIK3CA mutations in breast cancer, both in tissue and liquid biopsies. Such regulatory approvals not only validate the efficacy and safety of liquid biopsy methods but also contribute to the market’s growth by expanding the range of available diagnostic options.
Traditional methods like tissue biopsies are insufficient in capturing the entire genomics landscape of breast tumors for the detection of breast cancer. Liquid biopsy, as an alternative method, offers numerous clinical applications, including screening, therapy selection, mutation detection, disease prognosis, and assessment of drug response and resistance. This is particularly beneficial for patients who are unable to undergo invasive tumor biopsies. By providing a comprehensive and non-invasive approach to breast cancer detection, liquid biopsy plays a crucial role in improving patient outcomes and enhancing the overall management of the disease.
Get the free sample report of the Breast Cancer Liquid Biopsy Market
Comments
Post a Comment